• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
North America In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture - Product Image

North America In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

  • ID: 2017878
  • January 2012
  • Region: America, North America, United States
  • 439 pages
  • GlobalData

FEATURED COMPANIES

  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • Cepheid
  • F. Hoffmann-La Roche Ltd.
  • Grifols, S.A.
  • HORIBA, Ltd.
  • MORE

North America In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Summary

GlobalData’s new report, “North America In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture” provides key market data on the North America In Vitro Diagnostics market – Canada and United States. The report provides value (USD million) data for all the market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

- READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • Cepheid
  • F. Hoffmann-La Roche Ltd.
  • Grifols, S.A.
  • HORIBA, Ltd.
  • MORE

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What is This Report About?
3 In Vitro Diagnostics in North America
3.1 In Vitro Diagnostics Cross Country Comparison, USD Actual, 2003-2017
3.2 In Vitro Diagnostics, North America, Overall Revenue ($m), USD Actual, 2003-2017
3.3 In Vitro Diagnostics, North America, Company share (2009-2010)
4 In Vitro Diagnostics In Canada
4.1 In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, 2003-2017
4.2 In Vitro Diagnostics, Canada, Distribution Share (2009-2010)
4.3 In Vitro Diagnostics, Canada, Company share (2009-2010)
5 In Vitro Diagnostics In United States
5.1 In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, 2003-2017
5.2 In Vitro Diagnostics, United States Distribution Share (2009-2010)
5.3 In Vitro Diagnostics, United States, Company share (2009-2010)
6 Overview of Key Companies in North America In Vitro Diagnostics Market
6.1 Abbott Laboratories
6.2 Siemens Healthcare
6.3 F. Hoffmann-La Roche Ltd.
6.4 Beckman Coulter, Inc.
6.5 Ortho-Clinical Diagnostics Inc.
6.6 bioMerieux S.A.
6.7 Becton, Dickinson and Company
6.8 Bio-Rad Laboratories, Inc.
6.9 Alere Inc.
6.10 Sysmex Corporation
6.11 Qiagen N.V.
6.12 Gen-Probe Incorporated
6.13 DiaSorin S.p.A
6.14 Thermo Fisher Scientific Inc.
6.15 Immucor, Inc.
6.16 Hologic, Inc.
6.17 Phadia AB
6.18 Cepheid
6.19 Grifols, S.A.
6.20 Life Technologies Corporation
6.21 PerkinElmer, Inc.
6.22 HORIBA, Ltd.
6.23 Biomedica Diagnostics Inc.
6.24 OraSure Technologies, Inc.
7 In Vitro Diagnostics Market Pipeline Products
7.1 Clinical Chemisty Market Pipeline Products
7.2 Immuno Chemistry Market Pipeline Products
7.3 Haematology Market Pipeline Products
7.4 Infectious Immunology Market Pipeline Products
7.5 Microbiology Culture Market Pipeline Products
7.6 Histology and Cytology Market Pipeline Products
7.7 Genetic Testing Market Pipeline Products
8 Financial Deals Landscape
8.1 Merger
8.2 Acquisition
8.3 Partnerships
9 Recent Developments
9.1 Strategy And Business Planning
9.2 Product News
9.3 Legal and Regulatory
9.4 Government and Public Interest
10 Appendix
10.1 Definitions of Markets Covered in the Report
10.2 Research Methodology
10.3 Secondary Research
10.4 Primary Research
10.5 Models
10.6 Forecasts
10.7 Expert Panels
10.8 GlobalData Consulting
10.9 Currency Conversion
10.10 Contact Us
10.11 Disclaimer

1.1 List of Tables
Table 1: In Vitro Diagnostics, Cross Country Comparison, USD Actual, 2003-2017
Table 2: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Actual, 2003-2017
Table 3: In Vitro Diagnostics, North America, Cross-Category Analysis, 2003-2017
Table 4: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Actual, Historic, 2003-2010
Table 5: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
Table 6: In Vitro Diagnostics, North America, Company share by Revenue ($m), USD Actual, 2009-2010
Table 7: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, 2003-2017
Table 8: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, Historic, 2003-2010
Table 9: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
Table 10: Clinical Chemistry, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 11: Genetic Testing, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 12: Haematology, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 13: Histology And Cytology, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 14: Immuno Chemistry, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 15: Infectious Immunology, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 16: Microbiology Culture, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 17: In Vitro Diagnostics, Canada, Company share by Revenue ($m), USD Actual, 2009-2010
Table 18: Clinical Chemistry, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 19: Genetic Testing, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 20: Haematology, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 21: Histology And Cytology, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 22: Immuno Chemistry, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 23: Infectious Immunology, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 24: Microbiology Culture, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 25: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, 2003-2017
Table 26: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, Historic, 2003-2010
Table 27: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
Table 28: Clinical Chemistry, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 29: Genetic Testing, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 30: Haematology, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 31: Histology And Cytology, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 32: Immuno Chemistry, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 33: Infectious Immunology, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 34: Microbiology Culture, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 35: In Vitro Diagnostics, United States, Company share by Revenue ($m), USD Actual, 2009-2010
Table 36: Clinical Chemistry, United States, Company share by Revenue ($m), USD Actual 2009-2010
Table 37: Genetic Testing, United States, Company share by Revenue ($m), USD Actual 2009-2010
Table 38: Haematology, United States, Company share by Revenue ($m), USD Actual 2009-2010
Table 39: Histology And Cytology, United States, Company share by Revenue ($m), USD Actual 2009-2010
Table 40: Immuno Chemistry, United States, Company share by Revenue ($m), USD Actual 2009-2010
Table 41: Infectious Immunology, United States, Company share by Revenue ($m), USD Actual 2009-2010
Table 42: Microbiology Culture, United States, Company share by Revenue ($m), USD Actual 2009-2010
Table 43: Clinical Chemisty Market Pipeline Products
Table 44: Immuno Chemistry Market Pipeline Products
Table 45: Haematology Market Pipeline Products
Table 46: Infectious Immunology Market Pipeline Products
Table 47: Microbiology Culture Market Pipeline Products
Table 48: Histology and Cytology Market Pipeline Products
Table 49: Genetic Testing Market Pipeline Products
Table 50: Transonic Systems Merges With Scisense
Table 51: Vivakor Enters Into Memorandum Of Understanding To Merge With Resolution Biomedical
Table 52: Pall Corporation To Acquire ForteBio
Table 53: Shionogi Acquires Remaining 13% Joint Venture Stake In Ezose Sciences
Table 54: Agilent Technologies Completes Acquisition Of BioSystem Development
Table 55: Affymetrix To Acquire eBioscience For $330 Million
Table 56: AMAG Pharmaceuticals Plans For Sale Of The Company
Table 57: Vermillion Completes Acquisition Of Correlogic Systems For $0.4 Million
Table 58: Evonik Industries Acquires SurModics Pharmaceuticals From SurModics For $30 Million
Table 59: Everist Genomics Acquires Angiologix
Table 60: WuXi PharmaTech Acquires Abgent
Table 61: OPKO Health Acquires Claros Diagnostics
Table 62: Miraca Holdings Completes Acquisition Of Caris Diagnostics From Caris Life Sciences For $725 Million
Table 63: Bio-Rad Laboratories Acquires QuantaLife For $162 Million
Table 64: Sony Corporation of America Acquires Micronics
Table 65: PerkinElmer Completes Acquisition Of Caliper Life Sciences For $600 Million
Table 66: Thermo Fisher Scientific Acquires Intrinsic Bioprobes
Table 67: EMD Millipore To Acquire Amnis
Table 68: Modern Mobility Aids Finalizes Acquisition Of LumiGene Technologies
Table 69: OraSure Technologies Completes Acquisition Of DNA Genotek
Table 70: Thermo Fisher Scientific Acquires TREK Diagnostic Systems
Table 71: Solstas Lab Partners Acquires NextWave Diagnostic Laboratories
Table 72: Solstas Lab Partners Acquires Wilmington Pathology Laboratory
Table 73: Signal Genetics Acquires DiagnoCure Oncology Laboratories
Table 74: Luminex Completes Acquisition Of EraGen Biosciences
Table 75: Solstas Lab Partners Acquires Select Diagnostics
Table 76: BioMedical Technology Solutions Holdings To Acquire SharpsMD And 2000 Plus Consulting
Table 77: Nestle Health Science Completes Acquisition Of Prometheus Laboratories
Table 78: Abcam Acquires MitoSciences
Table 79: Health Diagnostic Laboratory Acquires Harris Scientific
Table 80: EKF Diagnostics Completes Acquisition of Stanbio Laboratory
Table 81: PositiveID Completes Acquisition Of MicroFluidic Systems
Table 82: Navitar Life Sciences To Acquire Modulation Optics
Table 83: Myriad Genetics Acquires Rules-Based Medicine
Table 84: Shrink Nanotechnologies To Acquire Nanopoint
Table 85: Novelos Therapeutics Acquires Cellectar
Table 86: LabCorp Completes Acquisition Of Orchid Cellmark For $85 Million
Table 87: ARAMARK Healthcare Acquires ReMedPar From Berkshire Partners
Table 88: Quest Diagnostics Completes Acquisition Of Celera
Table 89: CerMed International Acquires Viridis Bioscience
Table 90: Bruker BioSciences Completes Acquisition Of Michrom Bioresources
Table 91: Sparton Acquires Byers Peak
Table 92: Becton, Dickinson Completes Acquisition Of Accuri Cytometers
Table 93: Alastair John Gray Sells Stake In Phenomenex To Farajollah Farshad Mahjoor
Table 94: Trinity Biotech Acquires Phoenix Bio-Tech
Table 95: VWR International Acquires AMRESCO
Table 96: Sigma-Aldrich Acquires Resource Technology
Table 97: Technest Holdings Acquires AccelPath
Table 98: Endo Pharmaceuticals To Acquire A Pharmaceutical Company
Table 99: Illumina Acquires Epicentre Biotechnologies
Table 100: Quest Diagnostics Completes Acquisition Of Athena Diagnostics
Table 101: HistoRx Enters Into Licensing Agreement With Yale University
Table 102: BioTime Enters Into Distribution Agreement With USCN Life Science
Table 103: Critical Path Institute Signs Memorandum Of Understanding With The Hamner Institutes
Table 104: Tyrian Diagnostics Enters Into Distribution Agreement With NeoClone
Table 105: Global BioDiagnostics Extends Co-Development Agreement With Foundation for Innovative New Diagnostics
Table 106: Sony DADC Enters Into Co-Development Agreement With Axela
Table 107: Lineagen Enters Into Co-Development Agreement With Fast Forward
Table 108: Pathogenetix Enters Into Co-Development Agreement With Sagentia
Table 109: Bio-Rad Expands Co-Marketing Agreement With Siemens Medical
Table 110: Ezose Sciences Enters Into Co-Development Agreement With Merck
Table 111: Genome British Columbia Enters Into Co-Development Agreement With Genome Canada
Table 112: Fluxion Biosciences Enters Into Distribution Agreement With EMD Millipore
Table 113: Roche Enters Into Technology Integration Agreement With Labcyte
Table 114: Sony DADC BioSciences Enters Into Co-Development Agreement With Maven Biotechnologies
Table 115: Abbott Laboratories Expands Its Co-Development Agreement With GlaxoSmithKline Biologicals
Table 116: Olink Bioscience Enters Into Distribution Agreement With Bethyl Laboratories
Table 117: SuperNova Diagnostics Enters Into Co-Development Agreement With Concile
Table 118: OncoSec Medical Enters Into Research Agreement With Serametrix
Table 119: Bruker Enters Into Co-Development Agreement With Lawrence Berkeley National Laboratory
Table 120: Dako Enters Into Co-Development Agreement With Bristol-Myers
Table 121: Transgenomic Enters Into Distribution Agreement With ScreenCell
Table 122: Horizon Discovery Enters Into Co-Development Agreement With Promega
Table 123: Stemina Biomarker Discovery Enters Into Co-Development Agreement With ILS
Table 124: Psyche Systems Enters Into Technology Integration Agreement With Aperio Technologies
Table 125: Life Technologies Enters Into Co-Development Agreement With GlaxoSmithKline Biologicals
Table 126: PrognosDx Health Entetrs Into Co-Development Agreement With Accium BioSciences
Table 127: The Molecular Sciences Forms Joint Venture With VTT Technical Research
Table 128: DxTerity Diagnostics Enters Into Technology Integration Agreement With Caliper Life Sciences
Table 129: Gold Standard Diagnostics Extends Distribution Agreement With Fujirebio Diagnostics
Table 130: New England Biolabs Enters Into Co-Marketing Agreement With Rubicon Genomics
Table 131: WILEX Enters Into Co-Marketing Agreement With ALPCO Diagnostics
Table 132: Illumina Enters Into Co-Development Agreement With University Of North Texas Health Science Center
Table 133: Warnex Medical Laboratories Enters Into Distribution Agreement With deCODE genetics
Table 134: Absorption Systems Enters Into Co-Development Agreement With Temple University And Washington State University
Table 135: Oasis Diagnostics Enters Into Licensing Agreement With Two Researchers
Table 136: Bioo Scientific Enters Into Co-Development Agreement With JungWoo
Table 137: Accelr8 Technology Amends Licensing Agreement With SCHOTT
Table 138: Warnex PRO-DNA Enters Into Co-Development Agreement With National Research Council of Canada
Table 139: Orion Genomics Enters Into Licensing Agreement With QIAGEN
Table 140: Quantum Materials Enters Into Technology Integration Agreement With Nanoaxis
Table 141: Warnex Enters Into Licensing Agreement With Sorenson Forensics
Table 142: RedHill Biopharma Enters Into Licensing Agreement With UCF Research Foundation
Table 143: SuviCa Enters Into Licensing Agreement With University of Colorado
Table 144: Polymedco Enters Into Distribution Agreement With Cardinal Health
Table 145: Universal Biosensors Enters Into Co-Development Agreement With Siemens Healthcare Diagnostics
Table 146: LI-COR Biosciences Enters Into Licensing Agreement With Johns Hopkins University
Table 147: QIAGEN Enters Into Co-Development Agreement With Eli Lilly
Table 148: Sun Yat-sen University Enters Into Co-Development Agreement With BioDesign Institute
Table 149: Lumora Enters Into Licensing Agreement With 3M
Table 150: NuGEN Technologies Enters Into Co-Development Agreement With Advanced Liquid Logic And Broad Institute
Table 151: Biocept Enters Into Co-Marketing Agreement With Clarient
Table 152: Roche Enters Into Distribution Agreement With PerkinElmer
Table 153: Quanterix Enters Into Co-Development Agreement With STRATEC Biomedical
Table 154: DNA Diagnostics Center Enters Into Licensing Agreement
Table 155: Pronexus Enters Into Technology Integration Agreement With RealityCorp
Table 156: Carl Zeiss Enters Into Licensing Agreement With Prior Scientific
Table 157: EPIC Enters Into Distribution Agreement With Micro Imaging Technology
Table 158: BD Diagnostics Enters Into Co-Development Agreement With Lab21
Table 159: Procognia Enters Into Co-Development Agreement With Caerus Discovery
Table 160: BioMarCare Technologies Enters Into Co-Development Agreement With Ariadne
Table 161: Hycor Biomedical Signs Licensing Agreement With Axis-Shield
Table 162: Thermo Fisher Scientific Enters Into Licensing Agreement With Alere
Table 163: Quanterix Enters Into Co-Development Agreement With Sony DADC
Table 164: Canon U.S. Life Sciences Enters Into Co-Development Agreement With The University of Maryland
Table 165: Mayo Medical Laboratories Enters Into Licensing Agreement With Qiagen
Table 166: Rhoen-Klinikum Enters Into Co-Development Agreement With Siemens
Table 167: Proteome Sciences Enters Into Collaboration With Buck Institute
Table 168: Stratos Product Development Enters Into Co-Development Agreement With Response Biomedical
Table 169: Gold Standard Diagnostics Enters Into Distribution Agreement With Fujirebio Diagnostics
Table 170: Roche NimbleGen Enters Into Co-Marketing Agreement With Caliper Life Sciences
Table 171: Clinical Genomics Extends Its Licensing Agreement With Quest Diagnostics
Table 172: LaserGen Enters Into Co-Development Agreement With National Instruments
Table 173: Proteome Sciences Enters Into Co-Development Agreement With H. Lee Moffitt Cancer Center
Table 174: USD to Local Currency, North America, Average Exchange Rate 2003-2010

1.2 List of Figures
Figure 1: In Vitro Diagnostics, Cross Country Comparison, USD Actual, 2003-2017
Figure 2: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Actual, 2003-2017
Figure 3: In Vitro Diagnostics, North America, Cross-Category Analysis, 2003-2017
Figure 4: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Actual, Historic, 2003-2010
Figure 5: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
Figure 6: In Vitro Diagnostics, North America, Company share (%), 2010
Figure 7: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, 2003-2017
Figure 8: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, Historic, 2003-2010
Figure 9: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
Figure 10: In Vitro Diagnostics, Canada, Company share (%), 2010
Figure 11: Clinical Chemistry, Canada, Company share (%), 2010
Figure 12: Genetic Testing, Canada, Company share (%), 2010
Figure 13: Haematology, Canada, Company share (%), 2010
Figure 14: Histology And Cytology, Canada, Company share (%), 2010
Figure 15: Immuno Chemistry, Canada, Company share (%), 2010
Figure 16: Infectious Immunology, Canada, Company share (%), 2010
Figure 17: Microbiology Culture, Canada, Company share (%), 2010
Figure 18: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, 2003-2017
Figure 19: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, Historic, 2003-2010
Figure 20: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
Figure 21: In Vitro Diagnostics, United States, Company share (%), 2010
Figure 22: Clinical Chemistry, United States, Company share (%), 2010
Figure 23: Genetic Testing, United States, Company share (%), 2010
Figure 24: Haematology, United States, Company share (%), 2010
Figure 25: Histology And Cytology, United States, Company share (%), 2010
Figure 26: Immuno Chemistry, United States, Company share (%), 2010
Figure 27: Infectious Immunology, United States, Company share (%), 2010
Figure 28: Microbiology Culture, United States, Company share (%), 2010
Figure 29: Abbott Laboratories, Company Share (%), North America In Vitro Diagnostics Market, 2010
Figure 30: Siemens Healthcare, Company Share (%), North America In Vitro Diagnostics Market, 2010
Figure 31: F. Hoffmann-La Roche Ltd., Company Share (%), North America In Vitro Diagnostics Market, 2010
Figure 32: Beckman Coulter, Inc., Company Share (%), North America In Vitro Diagnostics Market, 2010
Figure 33: Ortho-Clinical Diagnostics Inc., Company Share (%), North America In Vitro Diagnostics Market, 2010
Figure 34: bioMerieux S.A., Company Share (%), North America In Vitro Diagnostics Market, 2010

Note: Product cover images may vary from those shown

Abbott Laboratories
Siemens Healthcare
F. Hoffmann-La Roche Ltd.
Beckman Coulter, Inc.
Ortho-Clinical Diagnostics Inc.
bioMerieux S.A.
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
Alere Inc.
Sysmex Corporation
Qiagen N.V.
Gen-Probe Incorporated
DiaSorin S.p.A
Thermo Fisher Scientific Inc.
Immucor, Inc.
Hologic, Inc.
Phadia AB
Cepheid
Grifols, S.A.
Life Technologies Corporation
PerkinElmer, Inc.
HORIBA, Ltd.
Biomedica Diagnostics Inc.
OraSure Technologies, Inc.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos